- Cool Tool – Label-free kinetic characterization in the palm of your handPosted 15 hours ago
- Cool Tool – SIDUS® technology for viral vector manufacturingPosted 2 days ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 24, 2017Posted 6 days ago
- Laminin cell culture matrices – The key to efficient derivation and reliable culture of stem cells and specialized cells lies within these extracellular matrix proteinsPosted 7 days ago
- Video – Fortem: A platform film built for bioprocessPosted 1 week ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 17, 2017Posted 2 weeks ago
- Cool Tool – The Human Protein AtlasPosted 2 weeks ago
- Optimization of Roche Liberase MNP-S GMP Grade in the Enzymatic Digestion of Human Umbilical Cord for the Isolation of Mesenchymal Stem CellsPosted 2 weeks ago
- Ask the Expert – Maximizing Transient Protein ProductionPosted 2 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 10, 2017Posted 3 weeks ago
Recombinant LONG R3IGF‐1 and rTransferrin Improved Growth and Productivity of Two Suspension Chinese Hamster Ovary Cell lines
Jinghui Qian, Rina Gandhi, Ariane Marolewski
LONG®R3IGF‐1 is a human IGF‐1 analog containing a 13 amino acid N‐terminal extension and a mutation at position 3. It activates the Type 1 IGF receptor, which is responsible for growth‐promoting and protein synthesis effects in CHO cells. A common growth factor supplement used in CHO media, insulin, acts primarily through the IGF‐R.
LONG®R3IGF‐1 has previously been shown to increase CHO productivity. However, past characterization studies used primarily DMEM/F12 media. As serum‐free media development has progressed, media have become richer and more complex. To establish the effect of LONG®R3IGF‐1 in media that meet today’s industry standards, the effect of LONG®R3IGF‐1 on the productivity of two antibody‐expressing cell lines was compared to that of insulin and no growth factor supplemented media. The studies were carried out in TPP Tubespin50mL bioreactor tubes. Media with LONG®R3IGF‐1 gave superior titers versus no growth factor or insulin in several instances. In addition, it was demonstrated that combination of LONG®R3IGF‐1 and rTransferrin gave higher titer than commercial ITS (rInsulin, rTransferrin, Selenium) solution in several modern commercial media types.
LONG®R3IGF‐1 is used at low, 10 –100 ng/mL, concentrations in cell culture and is currently used in several commercial antibody manufacturing processes. It represents a regulatory‐friendly method of enhancing serum‐free cell culture performance. LONG®R3IGF‐1 should, therefore, be considered as a media supplement to further optimize a protein‐free process or to replace insulin in existing processes.